Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 55 No. 3
PSYCHOPHARMACOLOGY BULLETIN

VOL 55 No. 3

Articles in This Issue

ORIGINAL RESEARCH

Kuwait-Mental Illness Disability Scale (K-MIDS): A Proposal

Bibi Alamiri, Hend FM FR Alenezi, Ahmed Naguy
Background It is widely agreed that the mentally ill constitute a sizeable chunk of the disabled population not only for those afflicted but also for their caregivers alike. Objective To assess the degree of disability...
Pages 20-25 Read Article
REVIEW ARTICLE

Quetiapine and Paediatric Psychiatrica: Evidence or Diffidence?

Ahmed Naguy, Saxby Pridmore, Hend FM FR Alenezi, Bibi Alamiri
The atypical antipsychotic, quetiapine has been on market for years now with long track record. In child and adolescent psychiatry, it is FDA-approved for childhood-onset schizophrenia and juvenile bipolar mood disorder. Its attractive pharmacological portfolio...
Pages 31-36 Read Article
COMPLICATED CASE HISTORY

Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood

Keming Gao, Buket Koparal, Evrim Bayrak Oruc, Margret A. Musso
In this case report, we present a patient with treatment-resistant depression (TRD) and comorbid generalized anxiety disorder, eating disorder, post-traumatic stress disorder, and borderline personality disorder. Over a 10-year period, our case transitioned from adolescence...
Pages 44-55 Read Article
COMPLICATED CASE HISTORY

Antipsychotic Treatment of Autistic Shutdowns—A Case Study

Kevin Colwell, Keenan Boianghu, Jillian Komornik, Susan Brown
The client was a 23-year-old, White (non-Latinx) female. She was 5′3′′ tall and weighed approximately 148 lbs. at the beginning of the study (she gained approximately 8 lbs during the antipsychotic treatment). She began tracking...
Pages 66-70 Read Article